Contributions
Abstract: PB1780
Type: Publication Only
Background
Emerging evidence have indicated that Exosomal microRNAs(miRNAs) in serum could be used as noninvasive biomarkers for tumor early diagnosis and/or prognosis. Here we hypothesized circulating exosomal miRNA can work as a candidate for diffuse large B cell lymphoma (DLBCL) diagnosis.
Aims
To investigate the expression level and significances of therapy monitoring of circulating exsomal miR-451a in diffuse large B cell patients.
Methods
We isolated exsomal RNAs fractions from serum of DLBCL patients before treatment，during treatment and after treatment, the serum of healthy controls was collected at the same time . Real time polymerase chain reaction（RT-PCR） were performed to detected the expression level of circulating exsomal miR-451a.
Results
A total of 112 participates, including 56 DLBCL patients and 56 healthy controls were enrolled. Circulating exsomal miR-451a were down-expression in DLBCL compared with healthy controls(P<0.0001)，and the area under the curve was 0.737（95%CI 0.645~0.816）. In patients who obtained remission ，including complete remission（CR） and partial remission（PR）, the levels of circulating exsomal miR-451a were gradually increased to healthy control. While in patients who did’t get remission ，including stable disease（SD） and progression disease（PD）, the changes of the level without significant difference and still lower than healthy controls. The AUC was 0.867（95%CI 0.728~0.951）when compared remission group and non-remission group.
Conclusion
Circulating exsomal miR-451a are suitable for therapy response monitoring in DLBCL.
Session topic: 21. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Diffuse large B cell lymphoma, Therapy, Treatment
Abstract: PB1780
Type: Publication Only
Background
Emerging evidence have indicated that Exosomal microRNAs(miRNAs) in serum could be used as noninvasive biomarkers for tumor early diagnosis and/or prognosis. Here we hypothesized circulating exosomal miRNA can work as a candidate for diffuse large B cell lymphoma (DLBCL) diagnosis.
Aims
To investigate the expression level and significances of therapy monitoring of circulating exsomal miR-451a in diffuse large B cell patients.
Methods
We isolated exsomal RNAs fractions from serum of DLBCL patients before treatment，during treatment and after treatment, the serum of healthy controls was collected at the same time . Real time polymerase chain reaction（RT-PCR） were performed to detected the expression level of circulating exsomal miR-451a.
Results
A total of 112 participates, including 56 DLBCL patients and 56 healthy controls were enrolled. Circulating exsomal miR-451a were down-expression in DLBCL compared with healthy controls(P<0.0001)，and the area under the curve was 0.737（95%CI 0.645~0.816）. In patients who obtained remission ，including complete remission（CR） and partial remission（PR）, the levels of circulating exsomal miR-451a were gradually increased to healthy control. While in patients who did’t get remission ，including stable disease（SD） and progression disease（PD）, the changes of the level without significant difference and still lower than healthy controls. The AUC was 0.867（95%CI 0.728~0.951）when compared remission group and non-remission group.
Conclusion
Circulating exsomal miR-451a are suitable for therapy response monitoring in DLBCL.
Session topic: 21. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Diffuse large B cell lymphoma, Therapy, Treatment